Leukemia

December 20, 2022

Re-Opened Trial: EA9152 for T-cell or B-cell Acute Lymphoblastic Leukemia

This study is investigating the safety and efficacy of venetoclax, a BCL-2 inhibitor, in combination with vincristine sulfate in the relapsed or refractory ALL population
October 13, 2022

Trial Spotlight: Yishai Ofran on the EA9181 Study for Acute Lymphoblastic Leukemia

This phase 3 study aims to explore whether treatment with a TKI plus blinatumomab may be superior to the usual treatment approach for acute lymphoblastic leukemia
October 13, 2022

Trial Results: ECOG-ACRIN Research Round-Up

Summaries of recently published ECOG-ACRIN research results
June 21, 2022

Now Enrolling: EA9213 for T-Cell Acute Lymphoblastic Leukemia

This single-arm phase II study aims to rid patients of residual disease following initial treatment
December 22, 2021

ECOG-ACRIN Research at ASH 2021

Researchers with the Leukemia, Lymphoma, and Myeloma Committees presented a range of findings pertaining to treatments, patient-reported outcomes, and genomics
September 30, 2021

From the Co-Chairs, September 2021

A focus on leukemia trials; an update regarding advanced practice providers; two important topics related to patient communication
September 30, 2021

Now Enrolling: Phase II of EA9152 for Acute Lymphoblastic Leukemia

This phase Ib/II study is testing the effects and safety of venetoclax in combination with liposomal vincristinein patients with B-ALL or T-ALL
September 30, 2021

Trial Spotlight: Selina Luger on the PrE0905 Study for FLT3 Mutated Acute Myeloid Leukemia

This phase II trial is exploring the targeted cancer therapy gilteritinib, a tyrosine kinase inhibitor that kills leukemia cells by binding to the mutant FLT3 protein and blocking its activity
March 31, 2021

Trial Spotlight: Amer Zeidan on the BLAST MRD CML 1 Study for Chronic Myeloid Leukemia

The EA9171 phase II trial aims to determine if adding pembrolizumab immunotherapy to standard-of-care TKI therapy helps more patients achieve undetectable minimal residual disease and allows them to discontinue TKI therapy
December 14, 2020

Now Enrolling: ECOG-ACRIN Opened Five New Trials in October

The five phase III trials span different cancer types: prostate, leukemia, anal, lung, and myeloma
January 14, 2020

Institution Spotlight: Fox Chase Cancer Center

A Standing Main Member of ECOG-ACRIN since 1971